Medacta International S.A. appears in FDA records as the applicant for the M-Vizion Femoral Revision System Extension, a modular femoral revision system for hip arthroplasty. The FDA record for K260173 lists the applicant at Strada Regina, Castel San Pietro, Switzerland, with correspondence directed to Medacta USA in Memphis, Tennessee. The device falls under product code LZO and regulation number 888.3353, the classification for hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prostheses. Medacta’s own case review describes the M-Vizion Modular Femoral Revision System as designed for primary through complex revision cases, with distal stem fixation uncoupled from proximal body reconstruction. [1][2][7]

The K260173 submission and its scope

FDA received K260173 on January 21, 2026, and issued a substantially equivalent decision on September 17, 2026, under the traditional review pathway with a summary statement. The advisory committee is orthopedic, and the third-party review flag is marked no. The clearance letter identifies the trade name as the M-Vizion Femoral Revision System Extension and assigns regulatory class II. [1][2]

The submission summary addresses mechanical and biological characterization rather than clinical performance. It describes range-of-motion evaluation of a Biolox Delta head according to ISO 21535, bacterial endotoxin testing by LAL method per European Pharmacopoeia §2.6.14, and pyrogen testing per USP chapter <151>. The subject devices are not labeled as non-pyrogenic or pyrogen free, and no clinical studies were conducted. [2]

Earlier clearance for the same device family

An earlier FDA clearance letter for the same trade name, K201471, is dated January 11, 2021, and references a submission dated December 22, 2020. That record lists product codes LZO and KWY and the same regulation number, 888.3353, with regulatory class II. The correspondence was directed to the same Medacta USA regulatory contact in Memphis, Tennessee. [3]

The K201471 summary likewise reports no clinical studies and repeats the pyrogenicity language: testing per USP chapter <151>, with devices not labeled as non-pyrogenic or pyrogen free. It also references modular connection testing according to IL 07.09.187 with worst-case evaluations and test reports. [3]

Product design as described by the manufacturer

Medacta’s published case review describes the M-Vizion Modular Femoral Revision System. Its discussion of modular revision hip stems separates distal stem fixation from proximal body reconstruction. That document describes the manufacturer’s design rationale; it does not independently establish a clinical advantage over other stem designs. [7]

Medacta’s revision hip page describes a Hip Revision Portfolio of femoral and acetabular solutions intended to help surgeons restore patient anatomy in complex revision surgeries. The page frames the platform around versatility of implants and instruments and reduced complexity of the surgical flow, and links to separate femoral and acetabular solution pages. [5]

Corporate identity and record context

The 2025 annual report lists M-Vizion among Medacta’s trademarks and gives the corporate address as Strada Regina 6874, Castel San Pietro, Switzerland, matching the applicant address in the FDA filing. The annual report covers hip, knee, shoulder, spine and sports medicine lines and describes certification and registration work in the countries where the company operates. [6][1]

The linked FDA collection for this profile contains one 510(k) record, K260173, with a substantially equivalent decision; the smaller record sample likewise contains that single entry. These counts describe the linked filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. No recall records are linked in the collection. [1]